What question did this study set out to answer?

The aim is to assess the safety and risk factors associated with gadolinium-based contrast agents in pediatric MRI.

April 10, 2026Pediatric RadiologyOpen Access

Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives

View Full Paper

Ask AI

Bookmark

Authors

This review evaluates renal safety and risk mitigation strategies for contrast agents in children, suggesting safer alternatives.

The aim is to assess the safety and risk factors associated with gadolinium-based contrast agents in pediatric MRI.
Review of existing literature on GBCA molecular structure and adverse effects.
Discussion of pediatric-specific pharmacokinetics.
Evidence-based strategies for risk mitigation.
Identification of at-risk children for nephrogenic systemic sclerosis.
Evaluation of alternative contrast agents like ferumoxytol.
GBCAs pose risks of nephrogenic systemic sclerosis, especially with impaired renal function.
Children with eGFR <30 mL/min/1.73 m² are at increased risk.
Evidence-based strategies effectively minimize cumulative exposure.
Ferumoxytol is emerging as a safer alternative contrast agent.

Jones et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark